NASDAQ:APVO

Aptevo Therapeutics - APVO Stock Forecast, Price & News

$3.12

-0.17 (-5.17%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.11
▼
$3.30
50-Day Range: $3.12
▼
$4.59
52-Week Range: $3.03
▼
$22.08

Volume: 65,743 shs
Average Volume: 41,954 shs
Market Capitalization: $15.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.50

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 685.3% Upside
$24.50 Price Target
Short Interest: Healthy
0.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($6.76) to ($7.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

987th out of 1,080 stocks

Pharmaceutical Preparations Industry

481st out of 535 stocks

3.3

Analyst's Opinion

Consensus Rating
Aptevo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.50, Aptevo Therapeutics has a forecasted upside of 685.3% from its current price of $3.12.
Amount of Analyst Coverage
Aptevo Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.80% of the outstanding shares of Aptevo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aptevo Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptevo Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aptevo Therapeutics does not currently pay a dividend.
Dividend Growth
Aptevo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APVO.

0.5

News and Social Media Coverage

News Sentiment
Aptevo Therapeutics has a news sentiment score of -1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aptevo Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for APVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Aptevo Therapeutics is held by insiders.
Percentage Held by Institutions
Only 15.63% of the stock of Aptevo Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aptevo Therapeutics are expected to decrease in the coming year, from ($6.76) to ($7.01) per share.
Price to Book Value per Share Ratio
Aptevo Therapeutics has a P/B Ratio of 12.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Stock News Headlines

September 19, 2022 | finance.yahoo.com

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

August 11, 2022 | finance.yahoo.com

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 4, 2022 | nasdaq.com

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

June 17, 2022 | msn.com

Aptevo Therapeutics's Return On Capital Employed Overview

June 11, 2022 | seekingalpha.com

Aptevo gains after disclosing additional remission data in leukemia trial

June 9, 2022 | finance.yahoo.com

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

May 12, 2022 | finance.yahoo.com

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

April 12, 2022 | finanznachrichten.de

Aptevo Therapeutics: APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

April 12, 2022 | finance.yahoo.com

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

March 30, 2022 | morningstar.com

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Morningstar

March 29, 2022 | finance.yahoo.com

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

March 24, 2022 | benzinga.com

Aptevo Therapeutics: Q4 Earnings Insights

March 24, 2022 | seekingalpha.com

Aptevo climbs as 2021 revenue more than doubles

March 24, 2022 | msn.com

Why Did Aptevo Therapeutics Stock Jump 25% Today?

March 24, 2022 | finance.yahoo.com

Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

February 9, 2022 | benzinga.com

Aptevo Therapeutics Earns $10M Non-Dilutive Milestone Payment On Sales Of RUXIENCE, Provides Company Update

February 9, 2022 | seekingalpha.com

Aptevo Therapeutics receives $10M in non-dilutive milestone payment on RUXIENCE sales

February 9, 2022 | nasdaq.com

Aptevo Therapeutics Gains On Milestone Payment On Sale Of Ruxience

February 9, 2022 | finance.yahoo.com

Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

January 21, 2022 | seekingalpha.com

Aptevo Therapeutics Board Chairman Fuad El-Hibri to retire

January 21, 2022 | finance.yahoo.com

Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

December 15, 2021 | finance.yahoo.com

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

November 23, 2021 | msn.com

Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial

November 23, 2021 | finance.yahoo.com

Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

November 16, 2021 | benzinga.com

Aptevo Therapeutics Announces Presentation Of 2 Abstracts At Upcoming American Society Of Hematology Annual Meeting

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Company Calendar

Last Earnings: 8/11/2022
Today: 9/24/2022
Next Earnings (Estimated): 11/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APVO
CUSIP: N/A
CIK: 1671584
Web: www.aptevotherapeutics.com
Phone: (206) 838-0500
Fax: 206-838-0503
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.50
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +685.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,460,000.00
Net Margins: -222.55%
Pretax Margin: 63.92%
Return on Equity: -481.02%
Return on Assets: -60.36%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 4.48
Quick Ratio: 4.48

Sales & Book Value

Annual Sales: $12.29 million
Price / Sales: 1.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.25 per share
Price / Book: 12.48

Miscellaneous

Outstanding Shares: 5,090,000
Free Float: 4,882,000
Market Cap: $15.88 million
Optionable: Optionable
Beta: 5.84

Key Executives

Mr. Marvin L. White (Age 60)
Pres, CEO & Director
Comp: $870.65k

Mr. Jeffrey G. Lamothe CA (Age 56)
Exec. VP & CFO
Comp: $590.56k

Dr. Jane A. Gross Ph.D. (Age 65)
Chief Scientific Officer
Comp: $515.17k

Ms. SoYoung Kwon J.D.
LL.M., Sr. VP, Gen. Counsel, Corp. Affairs & HR

Dr. Fatih M. Uckun M.D.
Ph.D., Chief Clinical Advisor & Consultant

Dr. Dirk Huebner M.D. (Age 59)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APVO Stock - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings or view top-rated stocks.
What is Aptevo Therapeutics' stock price forecast for 2022?: 2 brokers have issued twelve-month price targets for Aptevo Therapeutics' shares. Their APVO share price forecasts range from $13.00 to $36.00. On average, they anticipate the company's stock price to reach $24.50 in the next year. This suggests a possible upside of 685.3% from the stock's current price.
View analysts price targets for APVO or view top-rated stocks among Wall Street analysts.
How have APVO shares performed in 2022?: Aptevo Therapeutics' stock was trading at $7.87 on January 1st, 2022. Since then, APVO stock has decreased by 60.4% and is now trading at $3.12.
View the best growth stocks for 2022 here.
When is Aptevo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our APVO earnings forecast.
How were Aptevo Therapeutics' earnings last quarter?: Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its earnings results on Thursday, August, 11th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.33) by $0.53. Aptevo Therapeutics had a negative net margin of 222.55% and a negative trailing twelve-month return on equity of 481.02%.

What other stocks do shareholders of Aptevo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).
What is Aptevo Therapeutics' stock symbol?: Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
Who are Aptevo Therapeutics' major shareholders?: Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.40%), Virtu Financial LLC (0.25%), Franklin Resources Inc. (0.22%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Aptevo Therapeutics?: Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptevo Therapeutics' stock price today?: One share of APVO stock can currently be purchased for approximately $3.12.
How much money does Aptevo Therapeutics make?: Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $15.88 million and generates $12.29 million in revenue each year.
How can I contact Aptevo Therapeutics?: Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Aptevo Therapeutics - APVO Stock Forecast, Price & News

Aptevo Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows